Thanks to its banner HeartMate device, Thoratec ($THOR) handed in another quarter of solid revenue growth, but a spike in costs kept its net income from moving upward. Sales jumped 7% to $125.7 million on the quarter, with HeartMate accounting for $110 million of that figure. Despite the gains, Thoratec's profits came in at $18.2 million, exactly aligned with the first quarter of 2013. Results